HC Wainwright Has Pessimistic Outlook of DMRA Q3 Earnings

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) – Equities researchers at HC Wainwright reduced their Q3 2026 earnings per share (EPS) estimates for Damora Therapeutics, Inc. Common Stock in a note issued to investors on Friday, July 24th. HC Wainwright analyst M. Kapoor now anticipates that the company will earn ($0.33) per share for the quarter, down from their previous estimate of ($0.32). HC Wainwright has a “Buy” rating and a $45.00 price objective on the stock. The consensus estimate for Damora Therapeutics, Inc. Common Stock’s current full-year earnings is ($1.92) per share. HC Wainwright also issued estimates for Damora Therapeutics, Inc. Common Stock’s Q4 2026 earnings at ($0.34) EPS, Q1 2027 earnings at ($0.35) EPS, Q2 2027 earnings at ($0.37) EPS, Q3 2027 earnings at ($0.40) EPS and Q4 2027 earnings at ($0.42) EPS.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last issued its earnings results on Wednesday, May 13th. The company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.23).

A number of other research analysts have also weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research note on Thursday, June 18th. Royal Bank Of Canada started coverage on shares of Damora Therapeutics, Inc. Common Stock in a research report on Friday, April 24th. They set an “outperform” rating and a $40.00 target price for the company. Jefferies Financial Group assumed coverage on shares of Damora Therapeutics, Inc. Common Stock in a report on Monday. They issued a “buy” rating and a $50.00 target price on the stock. Wedbush reaffirmed an “outperform” rating and issued a $35.00 price target on shares of Damora Therapeutics, Inc. Common Stock in a research report on Friday, June 12th. Finally, TD Cowen assumed coverage on Damora Therapeutics, Inc. Common Stock in a research note on Monday, June 8th. They set a “buy” rating for the company. Two equities research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $43.38.

Damora Therapeutics, Inc. Common Stock Trading Up 2.2%

Shares of DMRA stock opened at $29.44 on Tuesday. The firm has a market capitalization of $1.81 billion, a PE ratio of -5.28 and a beta of 1.46. The firm has a fifty day simple moving average of $25.64 and a two-hundred day simple moving average of $25.86. Damora Therapeutics, Inc. Common Stock has a 12 month low of $2.45 and a 12 month high of $38.33.

Hedge Funds Weigh In On Damora Therapeutics, Inc. Common Stock

A number of hedge funds have recently bought and sold shares of the company. Ikarian Capital LLC purchased a new position in Damora Therapeutics, Inc. Common Stock during the 4th quarter worth $6,574,000. Jain Global LLC purchased a new stake in shares of Damora Therapeutics, Inc. Common Stock in the fourth quarter valued at about $2,774,000. Remedium Capital Partners LLC bought a new position in shares of Damora Therapeutics, Inc. Common Stock during the fourth quarter valued at about $2,772,000. Boothbay Fund Management LLC bought a new position in shares of Damora Therapeutics, Inc. Common Stock during the fourth quarter valued at about $2,204,000. Finally, Connective Capital Management LLC purchased a new position in Damora Therapeutics, Inc. Common Stock during the third quarter worth about $100,000. 14.20% of the stock is owned by hedge funds and other institutional investors.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto Inc is a clinical?stage biotechnology company developing small?molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin?3, an extracellular carbohydrate?binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase?like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin?3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin?3 inhibitor being evaluated for systemic fibrotic disorders.